Best Life Sciences Companies To Watch For 2014

With the Federal Reserve standing pat this week, the S&P 500 index has reached another all-time high.

Yet this bull market is proving to be even more fertile for investors in small-cap and micro-cap stocks. Both the iShares Russell Microcap Index and the Russell 2000 Small Cap Index are outperforming the S&P 500 by a solid margin over the past two years.

With no end in sight to the bull market, there's no reason to stop focusing on these small companies at this juncture. If the economy can manage to build a head of steam in 2014 and 2015, then these small stocks should see even deeper investor interest.

Here are three stocks that all trade below $5 and sport market values below $500 million -- and are poised for solid upside if this rally continues.

1. Lionbridge Technologies (Nasdaq: LIOX) I took note of heavy insider buying at this language translation services firm back in July, and though shares are up nearly 10% since then, the company's outlook has brightened markedly. 

On the second-quarter conference call, management delivered its most upbeat discussion of business trends in several years, noting that Lionbridge is seeing an expansion in its relationship with Microsoft (Nasdaq: MSFT), the return of several other large tech clients that had dropped off in the past few years, and a rising order book with manufacturing and life sciences clients. 

Top 5 Penny Stocks To Own For 2015: Radioshack Corporation(RSH)

RadioShack Corporation engages in the retail sale of consumer electronic goods and services through its RadioShack store chain and kiosk operations. Its products include postpaid and prepaid wireless handsets and communication devices, such as scanners and global positioning system (GPS) products; home entertainment, wireless, music, computer, video game, and GPS accessories; media storage, power adapters, digital imaging products, and headphones; home audio and video end-products, personal computing products, residential telephones, and voice over Internet protocol products; digital cameras, digital music players, toys, satellite radios, video gaming hardware, camcorders, and general radios; general and special purpose batteries and battery chargers; and wires and cables, connectivity products, components and tools, and hobby products. The company also provides consumers access to third-party services, such as prepaid wireless airtime and extended service plans in its ser vice platform. In addition, it manufactures various products, including telephones, antennas, wires, and cable products, as well as various hard-to-find parts and accessories for consumer electronics products; and provides repair services. As of March 31, 2011, the company operated 4,467 company-operated retail stores under the RadioShack brand name in the United States; and 1,304 kiosks located in Target and Sam?s Club stores. As of December 31, 2010, it operated 211 company-operated stores under the RadioShack brand, 9 dealers, and 1 distribution center in Mexico; a network of 1,207 RadioShack dealer outlets, including 34 located outside of North America; and 4 distribution centers in the United States. Further, the company sells its products through its Website, radioshack.com. RadioShack Corporation was founded in 1899 and is based in Fort Worth, Texas.

Advisors' Opinion:

• [By Roberto Pedone]

  Another stock that insiders are jumping into here is RadioShack (RSH), which is involved in the retail sale of consumer electronics goods and services through its RadioShack store chain. Insiders are buying this stock into decent strength, since shares are up 17.4% so far in 2013.

  RadioShack has a market cap of $250 million and an enterprise value of $536 million. This stock trades at a cheap valuation, with a price-to-sales of 0.06 and a price-to-book of 0.48. Its estimated growth rate for this year is -101.7%, and for next year it's pegged at 44.4%. This is not a cash-rich company, since the total cash position on its balance sheet is $432 million and its total debt is $712.70 million.

  A director just bought 100,000 shares, or about $255,000 worth of stock, at $2.55 per share.

  From a technical perspective, RSH is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last three months, with shares dropping from its high of $4.28 to its recent low of $2.18 a share. During that move, shares of RSH have been consistently making lower highs and lower lows, which is bearish technical price action.

  If you're in the bull camp on RSH, then look for long-biased trades as long as this stock is trending above some near-term support at $2.46 and then once it breaks out above its 200-day at $2.92 and its 50-day at $3.14 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 3.21 million shares. If that breakout triggers soon, then RSH will set up to re-test or possibly take out its next major overhead resistance levels at $3.30 to $3.60.

• [By WWW.DAILYFINANCE.COM]

  #fivemin-widget-blogsmith-image-27790{display:none}.cke_show_borders #fivemin-widget-blogsmith-image-27790,#postcontentcontainer #fivemin-widget-blogsmith-image-27790{width:570px;height:411px;display:block} WEST BRIDGEWATER, Mass. -- It's been called a David vs. Goliath story, a "Tale of Two Arthurs" and even the "ultimate Greek tragedy," but the characters in this drama aren't Biblical or literary figures. They're grocery store owners. A workers' revolt at the Market Basket supermarket chain has led to empty store shelves, angry customers and support for a boycott from more than 100 state legislators and mayors. Industry analysts say worker revolts at non-union companies are rare, but what's happening at Market Basket is particularly unusual because the workers aren't asking for higher pay or better benefits. They are demanding the reinstatement of beloved former CEO Arthur T. Demoulas, who workers credit with keeping prices low, treating employees well and guiding the company's success. The New England grocery store chain is embroiled in a family feud featuring two cousins who have been at odds for decades. While earlier squabbles between Arthur T. Demoulas and Arthur S. Demoulas were fought in courtrooms, this dispute has spilled into Market Basket stores. For the past week, warehouse workers have refused to make deliveries to Market Basket's stores, leaving fruit, vegetable, seafood and meat shelves empty. Workers have held huge protest rallies and organized boycott petitions through social media, attracting thousands of supporters. Customers are defecting to other grocery stores. In some cases, customers have taped receipts from competitors to Market Basket windows. "We are going to go somewhere else from now on," said Soraya DeBarros, as she walked through a depleted produce department at the Market Basket in West Bridgewater this week. "I'm sad about it because of course I want to keep the low prices, but I want to support the workers." Despit

Best Life Sciences Companies To Watch For 2014: Trius Therapeutics Inc.(TSRX)

Trius Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibiotics for serious, life-threatening infections in the United States. Its lead product includes Torezolid Phosphate, which is in Phase-III clinical trials for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections. The company is also developing antibiotics for gram-negative infections using its proprietary discovery platform under two contracts funded by the National Institute of Allergy and Infectious Diseases, and Defense Threat Reduction Agency. It has a cooperative research and development agreement with Lawrence Livermore National Security LLC for the research and development of gram-negative biodefense pathogens; and a license agreement with Dong-A Pharmaceutical Co., Ltd. to develop and sell Torezolid Phosphate outside of Korea. The company was formerly known as Rx3 Pharmac euticals, Inc. and changed its name to Trius Therapeutics, Inc. in February 2007. Trius Therapeutics, Inc. was founded in 2004 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Bob's Stocks]

  Back on February 4th, I wrote an article regarding another antibiotic stock named Trius Therapeutics (TSRX). It was trading at $5.00 per share at the time, and I put a price per share prediction of $13.00. I also stated it was a takeover target. Yesterday, Cubist Pharmaceuticals bought Trius Therapeutics for $13.50 a share. You can read that article here.

Best Life Sciences Companies To Watch For 2014: Prosiebensat 1 Media AG (PSM)

ProSiebenSat 1 Media AG is a Germany-based broadcasting company. It owns commercial television stations, pay television (TV) channels and radio networks in numerous European countries. The Company operates in three business segments, including Free TV German-speaking, Free TV International and Diversification. Free TV German-speaking segment includes the stations SAT.1, ProSieben, kabel eins and sixx, as well as the sales companies SevenOneMedia and SevenOne AdFactory. Free TV International constitute of commercial TV stations in the Benelux countries and the CEE (Central and Eastern Europe) region. The Diversification segment includes all activities not directly dependent on the TV advertising market, such as call TV, music, commerce or Pay TV. Advisors' Opinion:

• [By Jonathan Morgan]

  RWE AG (RWE) jumped 6.4 percent, leading a gauge of utilities higher. Deutz AG (DEZ) plunged the most in more than two years after an investor sold a 8.4 percent stake in the manufacturer of diesel engines. ProSiebenSat.1 Media AG (PSM) dropped 1.1 percent after Telegraaf Media Groep NV sold its stake in the company.

Best Life Sciences Companies To Watch For 2014: Ambit Biosciences Corp (AMBI)

Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Quizartinib

The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.

AC410

The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.

CSF1R Program

The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.

The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.

Advisors' Opinion:

• [By Wallace Witkowski]

  Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.